Bioventix PLC (FRA:51B)

Market Cap	101.41M -39.8%
Revenue (ttm)	14.38M -8.2%
Net Income	8.53M -5.2%
EPS	1.61 -5.1%
Shares Out	n/a
PE Ratio	11.90
Forward PE	n/a
Dividend	1.71 (8.57%)
Ex-Dividend Date	Apr 9, 2026

Volume	n/a
Open	18.50
Previous Close	19.40
Day's Range	18.50 - 18.50
52-Week Range	14.90 - 33.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 12
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 51B

Financial Performance

In fiscal year 2025, Bioventix's revenue was 13.12 million, a decrease of -3.61% compared to the previous year's 13.61 million. Earnings were 7.58 million, a decrease of -6.33%.

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error